Current view on novel vaccine technologies to combat human infectious diseases

Matić, Zrinka; Šantak, Maja (2022) Current view on novel vaccine technologies to combat human infectious diseases. Applied microbiology and biotechnology, 106 (1). pp. 25-56. ISSN 0175-7598

Preview

PDF - Published Version - article
Available under License Creative Commons Attribution.
Download (1MB) | Preview

Official URL: https://link.springer.com/article/10.1007/s00253-0...

Abstract

Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re- emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1–3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines.

Item Type:

Article

Uncontrolled Keywords:

Vaccine ; Immune response ; Novel technologies ; Infectious diseases ; Clinical trials ; Adjuvant

Subjects:

NATURAL SCIENCES > Biology
BIOMEDICINE AND HEALTHCARE > Public Health and Health Care
BIOTECHNICAL SCIENCES > Biotechnology

Divisions:

Division of Physical Chemistry

Projects: